Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.

ABSTRACT:

Introduction

Therapeutic options for diffuse malignant peritoneal mesothelioma (DMPM) are limited to surgery and locoregional chemotherapy. Despite improvements in survival rates, patients eventually succumb to disease progression. We investigated splicing deregulation both as molecular prognostic factor and potential novel target in DMPM, while we tested modulators of SF3b complex for antitumor activity.

Methods

Tissue-microarrays of 64 DMPM specimens were subjected to immunohistochemical assessment of SF3B1 expression and correlation to clinical outcome. Two primary cell cultures were used for gene expression profiling and in vitro screening of SF3b modulators. Drug-induced splicing alterations affecting downstream cellular pathways were detected through RNA sequencing. Ul

SUBMITTER: Sciarrillo R 

PROVIDER: S-EPMC6355829 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature